**Supplementary data**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table S1.** Nuclear EGFR expression and clinical-pathological data of NSCLC patients. NSCLC - non-small cell lung carcinoma; AC - adenocarcinoma; LSCC - squamous cell carcinoma. Significant P-values are given in bold. | | | | | | |
| **Parameters** | **All cases (N=238)** | | **AC (N=149)** | | **LSCC (N=89)** | |
| Score ± SD | P-value | Score ± SD | P-value | Score ± SD | P-value |
| **Histological type** |  |  |  |  |  |  |
| AC | 3.107±0.9874 | **<0.001** |  |  |  |  |
| LSCC | 3.528±0.8406 |  |  |
| **Age (years)** |  |  |  |  |  |  |
| ≤65 | 3.287±0.8862 | 0.91 | 3.135±0.9555 | 0.90 | 3.561±0.6726 | 0.95 |
| >65 | 3.244±1.019 | 3.080±1.024 | 3.500±0.9676 |
| **Gender** |  |  |  |  |  |  |
| Male | 3.252± 1.058 | 0.64 | 3.071±1.110 | 0.69 | 3.517±0.9223 | 0.84 |
| Female | 3.284± 0.7809 | 3.156±0.8012 | 3.548±0.6752 |
| **Malignancy grade** |  |  |  |  |  |  |
| G1, G2 | 3.238±1.069 | 0.90 | 2.960±1.179 | 0.25 | 3.513±0.8717 | 0.68 |
| G3 | 3.310±0.7203 | 3.257±0.7226 | 3.615±0.6504 |
| **Tumour size** |  |  |  |  |  |  |
| pT1 | 3.293± 0.8346 | 0.79 | 3.196±0.8184 | 0.27 | 3.579±0.8377 | 0.83 |
| pT2-pT4 | 3.228± 1.008 | 3.000±1.091 | 3.493±0.8335 |
| **Lymph nodes** |  |  |  |  |  |  |
| pN0 | 3.259±0.9980 | 0.85 | 3.049±1.005 | 0.58 | 3.541±0.9233 | 0.48 |
| pN1, pN2 | 3.235±0.8699 | 3.130±0.9722 | 3.444±0.5774 |
| **Stage** |  |  |  |  |  |  |
| I | 3.216±0.9505 | 0.41 | 3.048±0.9233 | 0.44 | 3.474±0.9512 | 0.85 |
| II-IV | 3.279±0.9557 | 3.097±1.050 | 3.540±0.7343 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table S2.** Cytoplasmic EGFR expression and clinical-pathological data of NSCLC patients. NSCLC - non-small cell lung carcinoma; AC - adenocarcinoma; LSCC - squamous cell carcinoma. Significant P-values are given in bold. | | | | | | |
| **Parameters** | **All cases (N=239)** | | **AC (N=149)** | | **LSCC (N=90)** | |
| Score ± SD | P-value | Score ± SD | P-value | Score ± SD | P-value |
| **Histological type** |  |  |  |  |  |  |
| AC | 3.664±1.166 | **<0.001** |  |  |  |  |
| LSCC | 4.556±1.358 |  |  |
| **Age (years)** |  |  |  |  |  |  |
| ≤65 | 4.000±1.305 | 0.98 | 3.608±1.145 | 0.60 | 4.707±1.289 | 0.40 |
| >65 | 4.000±1.325 | 3.720±1.192 | 4.429±1.414 |
| **Gender** |  |  |  |  |  |  |
| Male | 3.986±1.301 | 0.81 | 3.624±1.112 | 0.72 | 4.508±1.382 | 0.55 |
| Female | 4.021±1.337 | 3.719±1.240 | 4.645±1.330 |
| **Malignancy grade** |  |  |  |  |  |  |
| G1, G2 | 4.000±1.327 | 0.92 | 3.453±1.082 | **0.03** | 4.532±1.334 | 0.52 |
| G3 | 4.000±1.294 | 3.878±1.216 | 4.692±1.548 |
| **Tumour size** |  |  |  |  |  |  |
| pT1 | 3.880±1.354 | 0.15 | 3.768±1.236 | 0.63 | 4.211±1.619 | 0.13 |
| pT2-pT4 | 4.087±1.285 | 3.613±1.097 | 4.629±1.276 |
| **Lymph nodes** |  |  |  |  |  |  |
| pN0 | 3.958±1.284 | 0.31 | 3.537±1.045 | 0.11 | 4.516±1.364 | 0.74 |
| pN1, pN2 | 4.123±1.345 | 3.889±1.284 | 4.593±1.366 |
| **Stage** |  |  |  |  |  |  |
| I | 3.873±1.295 | 0.09 | 3.594±1.094 | 0.46 | 4.342±1.475 | 0.17 |
| II-IV | 4.138±1.308 | 3.750±1.207 | 4.686±1.257 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table S3.** Membranous EGFR expression and clinical-pathological data of NSCLC patients. NSCLC - non-small cell lung carcinoma; AC - adenocarcinoma; LSCC - squamous cell carcinoma. Significant P-values are given in bold. | | | | | | |
| **Parameters** | **All cases (N=239)** | | **AC (N=149)** | | **LSCC (N=90)** | |
| Score ± SD | P-value | Score ± SD | P-value | Score ± SD | P-value |
| **Histological type** |  |  |  |  |  |  |
| AC | 0.09396±0.4084 | **<0.001** |  |  |  |  |
| LSCC | 0.4111±0.8727 |  |  |
| **Age (years)** |  |  |  |  |  |  |
| ≤65 | 0.2348±0.6666 | 0.55 | 0.1216±0.4668 | 0.44 | 0.4390±0.8958 | 0.73 |
| >65 | 0.1935±0.6205 | 0.06667±0.3422 | 0.3878±0.8616 |
| **Gender** |  |  |  |  |  |  |
| Male | 0.1944±0.6289 | 0.48 | 0.08235±0.3846 | 0.67 | 0.3559±0.8461 | 0.38 |
| Female | 0.2421±0.6639 | 0.1094±0.4407 | 0.5161±0.9263 |
| **Malignancy grade** |  |  |  |  |  |  |
| G1, G2 | 0.2368±0.6783 | 0.51 | 0.06667±0.3422 | 0.44 | 0.4026±0.8624 | 0.87 |
| G3 | 0.1724±0.5748 | 0.1216±0.4668 | 0.4615±0.9674 |
| **Tumour size** |  |  |  |  |  |  |
| pT1 | 0.2000±0.6151 | 0.89 | 0.1250±0.4695 | 0.39 | 0.4211±0.9016 | 0.92 |
| pT2-pT4 | 0.2267±0.6670 | 0.06250±0.3316 | 0.4143±0.8763 |
| **Lymp nodes** |  |  |  |  |  |  |
| pN0 | 0.2083±0.6464 | 0.73 | 0.04878±0.3104 | 0.11 | 0.4194±0.8787 | 0.88 |
| pN1, pN2 | 0.2346±0.6571 | 0.1481±0.4917 | 0.4074±0.8884 |
| **Stage** |  |  |  |  |  |  |
| I | 0.1961±0.6455 | 0.58 | 0.06250±0.3507 | 0.45 | 0.4211±0.9192 | 0.89 |
| II-IV | 0.2358±0.6539 | 0.1111±0.4297 | 0.4118±0.8527 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table S4.** EGFR mRNA expression and clinical-pathological data of NSCLC patients. NSCLC - non-small cell lung carcinoma; AC - adenocarcinoma; LSCC - squamous cell carcinoma. Significant P-values are given in bold. | | | | | | |
| **Parameters** | **All cases (N=170)** | | **AC (N=104)** | | **LSCC (N=66)** | |
| Number of mRNA  copies/cell ± SD | P-value | Number of mRNA  copies/cell ± SD | P-value | Number of mRNA  copies/cell ± SD | P-value |
| **Histological type** |  |  |  |  |  |  |
| AC | 1.226±1.696 | 0.38 |  |  |  |  |
| LSCC | 1.198±2.084 |  |  |
| **Age (years)** |  |  |  |  |  |  |
| ≤65 | 1.376±2.131 | >0.99 | 1.410±1.980 | 0.85 | 1.317±2.404 | 0.78 |
| >65 | 1.075±1.565 | 1.055±1.378 | 1.105±1.823 |
| **Gender** |  |  |  |  |  |  |
| Male | 1.256±2.024 | 0.66 | 1.217±1.867 | 0.26 | 1.305±2.225 | 0.22 |
| Female | 1.150±1.550 | 1.237±1.471 | 0.9500±1.741 |
| **Malignancy grade** |  |  |  |  |  |  |
| G1, G2 | 1.080±1.727 | 0.21 | 1.010±1.399 | 0.40 | 1.143±1.985 | 0.57 |
| G3 | 1.438±2.032 | 1.426±1.922 | 1.505±2.675 |
| **Tumour size** |  |  |  |  |  |  |
| pT1 | 1.439±1.942 | 0.25 | 1.386±1.678 | 0.53 | 1.565±2.531 | 0.49 |
| pT2-pT4 | 1.203±1.869 | 1.304±1.807 | 1.090±1.949 |
| **Lymph nodes** |  |  |  |  |  |  |
| pN0 | 1.321±1.925 | 0.28 | 1.288±1.729 | 0.95 | 1.362±2.161 | 0.07 |
| pN1, pN2 | 1.157±1.838 | 1.355±1.817 | 0.7921±1.871 |
| **Stage** |  |  |  |  |  |  |
| I | 1.353±1.985 | 0.38 | 1.138±1.591 | 0.55 | 1.741±2.539 | 0.07 |
| II-IV | 1.219±1.821 | 1.521±1.883 | 0.8666±1.700 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table S5.** SATB1 mRNA expression and clinical-pathological data of NSCLC patients. NSCLC - non-small cell lung carcinoma; AC - adenocarcinoma; LSCC - squamous cell carcinoma. Significant P-values are given in bold. | | | | | | |
| **Parameters** | **All cases (N=170)** | | **AC (N=104)** | | **LSCC (N=66)** | |
| Number of mRNA  copies/cell ± SD | P-value | Number of mRNA  copies/cell ± SD | P-value | Number of mRNA  copies/cell ± SD | P-value |
| **Histological type** |  |  |  |  |  |  |
| AC | 0.2837±0.6372 | 0.27 |  |  |  |  |
| LSCC | 0.4214±0.8613 |  |  |
| **Age (years)** |  |  |  |  |  |  |
| ≤65 | 0.1344±0.4396 | **<0.001** | 0.09420±0.3356 | **<0.001** | 0.2038±0.5775 | 0.06 |
| >65 | 0.5131±0.8798 | 0.4591±0.7873 | 0.5919±1.006 |
| **Gender** |  |  |  |  |  |  |
| Male | 0.3265±0.7307 | 0.40 | 0.2774±0.6281 | 0.40 | 0.3885±0.8457 | 0.57 |
| Female | 0.3538±0.7420 | 0.2915±0.6554 | 0.4970±0.9139 |
| **Malignancy grade** |  |  |  |  |  |  |
| G1, G2 | 0.3626±0.7979 | 0.54 | 0.2530±0.6392 | 0.74 | 0.4605±0.9114 | 0.33 |
| G3 | 0.2948±0.6144 | 0.3120±0.6401 | 0.2020±0.4677 |
| **Tumour size** |  |  |  |  |  |  |
| pT1 | 0.2745±0.7244 | 0.25 | 0.2475±0.6590 | 0.52 | 0.3393±0.8843 | 0.45 |
| pT2-pT4 | 0.3693±0.7520 | 0.3011±0.6382 | 0.4455±0.8619 |
| **Lymph nodes** |  |  |  |  |  |  |
| pN0 | 0.3888±0.7970 | 0.25 | 0.3157±0.6657 | 0.55 | 0.4789±0.9338 | 0.35 |
| pN1, pN2 | 0.2741±0.6495 | 0.2714±0.6595 | 0.2789±0.6485 |
| **Stage** |  |  |  |  |  |  |
| I | 0.2940±0.6866 | 0.68 | 0.2278±0.5630 | 0.94 | 0.4132±0.8667 | 0.77 |
| II-IV | 0.3742±0.7854 | 0.3296±0.7129 | 0.4263±0.8688 |